Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Increase in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 126,917 shares, a growth of 59.6% from the March 15th total of 79,512 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 152,950 shares, the days-to-cover ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jupiter Neurosciences has an average rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Several hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the last quarter. Allen Capital Group LLC bought a new stake in shares of Jupiter Neurosciences during the fourth quarter valued at approximately $31,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of Jupiter Neurosciences during the fourth quarter valued at approximately $135,000.

Jupiter Neurosciences Trading Up 0.1%

Shares of Jupiter Neurosciences stock opened at $0.40 on Tuesday. The stock has a market capitalization of $14.48 million, a price-to-earnings ratio of -1.53 and a beta of 2.80. Jupiter Neurosciences has a 1-year low of $0.31 and a 1-year high of $3.33. The firm’s 50-day moving average price is $0.47 and its two-hundred day moving average price is $0.96.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($0.07) earnings per share for the quarter. The business had revenue of $0.02 million for the quarter. As a group, equities research analysts predict that Jupiter Neurosciences will post -0.06 EPS for the current year.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.